

11th January 2022

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000
 F +91 22 6606 1200
 E info@ajantapharma.com
 W www.ajantapharma.com

Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no.
BSE LIMITED	National Stock Exchange of India,

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find quarterly compliance Report on Corporate Governance (CG) for the quarter ended on 31st December 2021.

Thanking You,

Yours faithfully,

GAURANG SHAH *VP – Legal & Company Secretary*

Encl.: a/a



Ajanta House Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

14.01.1972 1

0

Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

1. Name of Listed Entity : Ajanta Pharma Limited : 31st December 2021

Executive

Director

29.04.2000

2. Quarter ending

Μ.

Yogesh

Agrawal

Mr.

00073872

00073673

£t

AACPA2793C

L Composition of Board of Directors

I. Con	I. Composition of Board of Directors											
Titl	Name of the	PAN\$	Category	Initial Date	Date of Re-	Date	Tenure	Date of	No of	No of	Number of	No of post of
e	Director	& DIN	(Chairperson	of	appointment	of	*	Birth	Direct	Indepen	membershi	Chairperson
(Mr.			/Executive/	Appointmen		Cess			orship	dent	ps in	in Audit/
/			Non-	t		ation			in	Director	Audit/	Stakeholder
Ms.)			Executive/						listed	ship in	Stakeholde	Committee
			independent/						entitie	listed	r	held in
			Nominee) ^{&}						s	entities	Committee	listed
									includi	includin	(S)	entities
									ng this	g this	including	including
									listed	listed	this listed	this listed
									entity	entity	entity	entity (Refer
									(in	[in	(Refer	Regulation
									refere	referen	Regulation	26(1) of
									nce to	ce to	26(1) of	Listing
									Regula	proviso	Listing	Regulations)
									tion	to	Regulation	
									17A (1)	regulati	s)	
										on 17A		
										(1)]		
Mr.	Mannalal B.	AACPA2742D	Chairperson &	31.12.1979	30.07.2020	-	-	26.03.1947	1	0	Audit - 1	Of 1 SRC
	Agrawal	£	Non-Executive		#						SRC - 1	Committee
		00073828	Director									
Mr.	Madhusudan	AAHPA8178J	Executive	31.12.1979	01.04.2020	-	-	29.03.1955	1	0	None	None
	B. Agrawal	£	Director									

01.04.2018

-

-

None

None



Ajanta House Charkop, Kandivli West,

Mumbai 400 067

T +91 22 6606 1000

F +91 22 6606 1200

E info@ajantapharma.com

0							eC ajante					
				India		W	www.ajanta	apharma.com				
Mr.	Rajesh M. Agrawal	AACPA2792D & 00302467	Executive Director	30.04.2013	01.05.2018	-	-	31.03.1976	1	0	Audit - None SRC - 1	None
Mr.	Chandrakant Khetan	AAHPK5606M & 00234118	Independent Director	20.10.2008	18.07.2019	-	158 months	24.01.1946	1	1	Audit - 1 SRC - None	Of 1 Audit Committee
Mr.	K H Viswanathan	ALJPK1873B & 06563472	Independent Director	30.04.2013	18.07.2019	-	104 months	11.01.1946	1	1	Audit - 1 SRC - None	None
Mr.	Prabhakar Dalal	ADKPD7258G & 00544948	Independent Director	13.06.2014	18.07.2019	-	89.5 months	09.01.1953	2	2	Audit - 3 (*) SRC - 1	Of 1 Audit Committee Of 1 SRC
Dr.	Anjana Grewal	AFNPG6211K & 06896404	Independent Director	13.06.2014	18.07.2019	-	89.5 months	01.11.1953	1	1	Audit - 1 (*) SRC - 1	None
Whet	her regular Cha	irperson appoir	ted : Yes	•		•	•	•		•		•
Whet	her Chairpersor	n is related to m	nanaging director	or CEO : Yes								
		•	p of unlisted con	npanies also								
# Re-	appointed purs	uant to retirem	ent by rotation									

II. Composition of C	Committees				
Name of	Whether Regular	Name of Committee	Category (Chairperson/Executive/Non Executive/Independent/N	Date of	Date of
Committee	chairperson	members	ominee)\$	Appointment	Cessation
	appointed				
1. Audit	Yes	Mr. Chandrakant Khetan	Independent Director, Chairman of Committee	23-10-2008	
Committee		Mr. Mannalal B.	Non-Executive Chairperson of Company, Member of Committee	15-07-2000	
Agrawal		Agrawal	Independent Director, Member of Committee	29-07-2013	
		Mr. K H Viswanathan	Independent Director, Member of Committee	05-08-2014	
		Mr. Prabhakar Dalal			
2. Nomination &	Yes	Mr. Prabhakar Dalal	Independent Director, Chairman of Committee	05-08-2014	
Remuneration		Mr. Chandrakant Khetan		27-01-2014	
			Independent Director, Member of Committee	29-07-2013	
		Dr. Anjana Grewal	Independent Director, Member of Committee	30-04-2019	



Dr. Anjana Grewal

3. Risk

Management Committee

4. Stakeholders Relationship

Committee

t	a pharma l	<i>limited</i>	janta Ho harkop, 1umbai 4 ndia	Kandivli West,	 T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com 	
	Yes	Mr. Yogesh M. Ag Mr. Rajesh M. Ag Mr. K H Viswanat Mr. Arvind K. Agr	awal nan	Joint Managing Independent Di	ector, Chairman of Committee09-08-2017ng Director, Member of Committee09-08-2017Director, Member of Committee30-04-2021ial Officer, Member of Committee09-08-2017	
	Yes	Mr. Mannalal Agrawal Mr. Rajesh M. Agr		Executive Direc	ve Chairperson of Company, Chairman of Committee30-04-2019rector, Member of Committee29-07-2013Director, Member of Committee05-08-2014	

III. Meeting of Board of Directors					
Date(s) of Meeting (if	Date(s) of Meeting (if	Whether requirement	Number of	Number of Independent	Maximum gap between any two
any) in the previous	any) in the relevant	of Quorum met*	Directors	directors present *	consecutive (in number of days)
quarter	quarter		present *		
29 th July 2021	29 th October 2021	Yes	8	4	91
28 th December 2021 Yes 8 4 59					
* to be filled in only for	the current quarter meetin	gs		•	

IV. Meeting of Committees	IV. Meeting of Committees						
Date(s) of meeting of the	Whether requirement	Number of	Number of	Date(s) of meeting of the	Maximum gap between any two		
committee in the relevant	of Quorum met*	Directors	Independent	committee in the	consecutive meetings in number		
quarter		present *	directors present *	previous quarter	of days*		
29 th October 2021	Yes	4	3	29 th July 2021	91		
* This information has to be m	andatorily be given for au	dit committee, fo	r rest of the committee	e giving this information is	optional		

**to be filled in only for the current quarter meetings

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA) refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Material RPTs are only with Wholly Owned subsidiary of the Company and shareholder's approval is not required for such RPTs as per Regulation 23(5) of the Listing Regulations.
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes



Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000
 F +91 22 6606 1200
 E info@ajantapharma.com
 W www.ajantapharma.com

Note:

- 1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.
- 2. If status is "No" details of non-compliance may be given here.

VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & Remuneration committee
 - c. Stakeholders relationship committee
 - d. Risk management committee (applicable to the top 1000 listed entities): Applicable
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.
- Name & Designation: Gaurang C Shah

Company Secretary / Compliance Officer / Managing Director / CEO / CFO : Company Secretary & Compliance Officer